ZA200702379B - Piperidine derivative or pharmaceutically acceptable salt thereof - Google Patents
Piperidine derivative or pharmaceutically acceptable salt thereof Download PDFInfo
- Publication number
- ZA200702379B ZA200702379B ZA200702379A ZA200702379A ZA200702379B ZA 200702379 B ZA200702379 B ZA 200702379B ZA 200702379 A ZA200702379 A ZA 200702379A ZA 200702379 A ZA200702379 A ZA 200702379A ZA 200702379 B ZA200702379 B ZA 200702379B
- Authority
- ZA
- South Africa
- Prior art keywords
- lower alkyl
- substituted
- pharmaceutically acceptable
- acceptable salt
- piperidine derivative
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title claims abstract description 20
- 150000003839 salts Chemical class 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 11
- 229940126121 sodium channel inhibitor Drugs 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- FNVFKCZSFNJFMY-VOTSOKGWSA-N 1-[4-[(e)-2-(2-methylphenyl)ethenyl]piperidin-1-yl]-2-morpholin-4-ylethanone Chemical compound CC1=CC=CC=C1\C=C\C1CCN(C(=O)CN2CCOCC2)CC1 FNVFKCZSFNJFMY-VOTSOKGWSA-N 0.000 claims 1
- FAJWWMZYKBEOPK-VOTSOKGWSA-N 1-[4-[(e)-2-(4-chlorophenyl)ethenyl]piperidin-1-yl]-2-(cyclohexylamino)ethanone Chemical compound C1=CC(Cl)=CC=C1\C=C\C1CCN(C(=O)CNC2CCCCC2)CC1 FAJWWMZYKBEOPK-VOTSOKGWSA-N 0.000 claims 1
- VNMXXVWEPDYBDD-OWOJBTEDSA-N 1-[4-[(e)-2-(4-chlorophenyl)ethenyl]piperidin-1-yl]-2-morpholin-4-ylethanone Chemical compound C1=CC(Cl)=CC=C1\C=C\C1CCN(C(=O)CN2CCOCC2)CC1 VNMXXVWEPDYBDD-OWOJBTEDSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical group C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 abstract description 14
- 102000018674 Sodium Channels Human genes 0.000 abstract description 14
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 208000004296 neuralgia Diseases 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 125000002252 acyl group Chemical group 0.000 abstract description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 7
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 150000001555 benzenes Chemical group 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940124707 pain therapeutics Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004254478 | 2004-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200702379B true ZA200702379B (en) | 2008-07-30 |
Family
ID=36000120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200702379A ZA200702379B (en) | 2004-09-01 | 2005-08-31 | Piperidine derivative or pharmaceutically acceptable salt thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080070898A1 (fr) |
| EP (1) | EP1785415B1 (fr) |
| JP (1) | JP5025266B2 (fr) |
| KR (1) | KR20070050961A (fr) |
| CN (1) | CN101014570A (fr) |
| AT (1) | ATE556052T1 (fr) |
| AU (1) | AU2005278469A1 (fr) |
| BR (1) | BRPI0514812A (fr) |
| CA (1) | CA2578604A1 (fr) |
| ES (1) | ES2384574T3 (fr) |
| IL (1) | IL181621A0 (fr) |
| MX (1) | MX2007002541A (fr) |
| NO (1) | NO20071480L (fr) |
| RU (1) | RU2347775C2 (fr) |
| WO (1) | WO2006025471A1 (fr) |
| ZA (1) | ZA200702379B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8044206B2 (en) * | 2003-03-07 | 2011-10-25 | Astellas Pharma Inc. | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl |
| US8809380B2 (en) | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3658797A (en) * | 1968-08-06 | 1972-04-25 | Lilly Co Eli | Novel 5-nitroimidazole antiparasitic agents |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| FR2522325B1 (fr) * | 1982-02-26 | 1985-08-09 | Delalande Sa | Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique |
| JPH0631230B2 (ja) * | 1987-02-20 | 1994-04-27 | 山之内製薬株式会社 | 飽和ヘテロ環カルボン酸アミド誘導体 |
| JPH0696532B2 (ja) * | 1988-08-11 | 1994-11-30 | 山之内製薬株式会社 | 血小板活性化因子拮抗剤 |
| JP2002523448A (ja) * | 1998-08-28 | 2002-07-30 | サイオス インコーポレイテッド | ｐ３８−αキナーゼのインヒビター |
| BR0107732A (pt) * | 2000-01-20 | 2003-03-11 | Eisai Ltd | Método para prevenir ou tratar uma doença |
| CN100508451C (zh) * | 2001-07-17 | 2009-07-01 | 夏普株式会社 | 生成用于检测在处理期间加密数据的虚假改造的数据的设备及方法 |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| WO2004011430A1 (fr) * | 2002-07-25 | 2004-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteur des canaux sodium |
| US8044206B2 (en) * | 2003-03-07 | 2011-10-25 | Astellas Pharma Inc. | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl |
-
2005
- 2005-08-31 BR BRPI0514812-0A patent/BRPI0514812A/pt not_active IP Right Cessation
- 2005-08-31 RU RU2007111957/04A patent/RU2347775C2/ru not_active IP Right Cessation
- 2005-08-31 ZA ZA200702379A patent/ZA200702379B/en unknown
- 2005-08-31 JP JP2006532764A patent/JP5025266B2/ja not_active Expired - Fee Related
- 2005-08-31 ES ES05781323T patent/ES2384574T3/es active Active
- 2005-08-31 EP EP05781323A patent/EP1785415B1/fr not_active Not-in-force
- 2005-08-31 US US11/661,446 patent/US20080070898A1/en not_active Abandoned
- 2005-08-31 MX MX2007002541A patent/MX2007002541A/es not_active Application Discontinuation
- 2005-08-31 AT AT05781323T patent/ATE556052T1/de active
- 2005-08-31 KR KR1020077005838A patent/KR20070050961A/ko not_active Application Discontinuation
- 2005-08-31 CN CNA2005800293270A patent/CN101014570A/zh active Pending
- 2005-08-31 CA CA002578604A patent/CA2578604A1/fr not_active Abandoned
- 2005-08-31 AU AU2005278469A patent/AU2005278469A1/en not_active Abandoned
- 2005-08-31 WO PCT/JP2005/015949 patent/WO2006025471A1/fr active Application Filing
-
2007
- 2007-02-28 IL IL181621A patent/IL181621A0/en unknown
- 2007-03-20 NO NO20071480A patent/NO20071480L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1785415B1 (fr) | 2012-05-02 |
| JP5025266B2 (ja) | 2012-09-12 |
| KR20070050961A (ko) | 2007-05-16 |
| ATE556052T1 (de) | 2012-05-15 |
| AU2005278469A1 (en) | 2006-03-09 |
| IL181621A0 (en) | 2007-07-04 |
| US20080070898A1 (en) | 2008-03-20 |
| CN101014570A (zh) | 2007-08-08 |
| MX2007002541A (es) | 2007-05-09 |
| ES2384574T3 (es) | 2012-07-09 |
| BRPI0514812A (pt) | 2008-06-24 |
| CA2578604A1 (fr) | 2006-03-09 |
| EP1785415A1 (fr) | 2007-05-16 |
| RU2347775C2 (ru) | 2009-02-27 |
| JPWO2006025471A1 (ja) | 2008-05-08 |
| WO2006025471A1 (fr) | 2006-03-09 |
| NO20071480L (no) | 2007-05-10 |
| EP1785415A4 (fr) | 2009-08-05 |
| RU2007111957A (ru) | 2008-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5942503A (en) | Use of Epinastine for the treatment of pain | |
| DE69733611T2 (de) | Verfahren und potenzierte zusammensetzung zur behandlung von migräne | |
| AU2018251118A1 (en) | Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof | |
| GB2240475A (en) | 5ht-3 antagonist for the prevention or reduction of dependence | |
| JPS60214733A (ja) | 高めた無痛覚を与える製薬製品 | |
| HU191643B (en) | Process for preparing new n-phenyl-n'-cycloalkyl-alkanoyl-piperazine derivatives | |
| US20100152141A1 (en) | Combinations comprising 5ht6 modulators and cholinesterase inhibitors | |
| WO2006125180B1 (fr) | Derives de piperazine: utilisation comme agents therapeutiques | |
| KR970001327A (ko) | 치환 피페리딘 유도체 | |
| WO2019109937A1 (fr) | Utilisation d'un agoniste de kor en combinaison avec un agoniste de mor dans la préparation d'un médicament pour le traitement de la douleur | |
| US7598265B2 (en) | Compositions and methods for treating CNS disorders | |
| Mizobe et al. | α2-Adrenoceptor agonists and anesthesia | |
| CA2529452C (fr) | Agent visant a faire baisser le cholesterol serique ou agent de prevention ou therapeutique pour l'atherosclerose | |
| US5057519A (en) | 5-HT3 antagonists: use in reducing opiate tolerance | |
| EP0627221A2 (fr) | Antagonistes de la substance P pour le traitement du vomissement | |
| CN1662232A (zh) | 改善脑功能的药物组合物和改善脑功能的方法 | |
| EP1123702A1 (fr) | Analgesiques | |
| CN1382145A (zh) | 神经性疼痛治疗剂和神经性疼痛的动物模型 | |
| US5519033A (en) | Azabicyclo derivatives for treatment of urinary incontinence | |
| ZA200702379B (en) | Piperidine derivative or pharmaceutically acceptable salt thereof | |
| JP3559572B2 (ja) | 急性痛および慢性痛用鎮痛剤 | |
| SK279940B6 (sk) | Použitie bisfenylalkylpiperazínov | |
| US7282515B2 (en) | Derivatives of azaspiro compounds for the treatment of pain | |
| AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
| WO2012074799A1 (fr) | Traitement d'inflammation avec certains agonistes des récepteurs alpha-7 de l'acide nicotinique en combinaison avec inhibiteurs d'acétylcholinestérase |